Second allogeneic stem cell transplantation for acute leukemia using a chemotherapy- Only cytoreduction with clofarabine, melphalan, and thiotepa Journal Article


Authors: Spitzer, B.; Perales, M. A.; Kernan, N. A.; Prockop, S. E.; Zabor, E. C.; Webb, N.; Castro-Malaspina, H.; Papadopoulos, E. B.; Young, J. W.; Scaradavou, A.; Kobos, R.; Giralt, S. A.; O'Reilly, R. J.; Boulad, F.
Article Title: Second allogeneic stem cell transplantation for acute leukemia using a chemotherapy- Only cytoreduction with clofarabine, melphalan, and thiotepa
Abstract: Relapse after allogeneic hematopoietic stem cell transplantation (alloHSCT) remains one of the leading causes of mortality in patients with leukemia. Treatment options in this population remain limited, with concern for both increased toxicity and further relapse. We treated 18 patients with acute leukemia for marrow ± extramedullary relapse after a previous alloHSCT with a myeloablative cytoreductive regimen including clofarabine, melphalan, and thiotepa followed by a second or third transplantation from the same or a different donor. All patients were in remission at the time of the second or third transplantation. All evaluable patients engrafted. The most common toxicity was reversible transaminitis associated with clofarabine. Two patients died from transplantation-related causes. Seven patients relapsed after their second or third transplanation and died of disease. Nine of 18 patients are alive and disease free, with a 3-year 49% probability of overall survival (OS). Patients whose remission duration after initial alloHSCT was >6 months achieved superior outcomes (3-year OS, 74%, 95% confidence interval, 53% to 100%), compared with those relapsing within 6 months (0%) (P <.001). This new cytoreductive regimen has yielded promising results with acceptable toxicity for second or third transplantations in patients with high-risk acute leukemia who relapsed after a prior transplantation, using various graft and donor options. This approach merits further evaluation in collaborative group studies. © 2016 American Society for Blood and Marrow Transplantation
Keywords: leukemia; transplantation; clofarabine; second
Journal Title: Biology of Blood and Marrow Transplantation
Volume: 22
Issue: 8
ISSN: 1083-8791
Publisher: Elsevier Inc.  
Date Published: 2016-08-01
Start Page: 1449
End Page: 1454
Language: English
DOI: 10.1016/j.bbmt.2016.05.001
PROVIDER: scopus
PMCID: PMC4989237
PUBMED: 27184623
DOI/URL:
Notes: Article -- Export Date: 1 September 2016 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Nancy Kernan
    512 Kernan
  2. Farid Boulad
    329 Boulad
  3. Susan E Prockop
    262 Prockop
  4. Sergio Andres Giralt
    1054 Giralt
  5. Emily Craig Zabor
    172 Zabor
  6. Miguel-Angel Perales
    918 Perales
  7. James W Young
    319 Young
  8. Richard O'Reilly
    748 O'Reilly
  9. Rachel Kobos
    75 Kobos
  10. Barbara Spitzer
    78 Spitzer
  11. Nicholas Michael Webb
    4 Webb